Investors in Zynex, Inc. Urged to Respond Amid Class Action Lawsuit

Class Action Lawsuit Against Zynex, Inc.

Investors who have incurred financial losses due to their investments in Zynex, Inc. (OTCMKTS: ZYXIQ) are encouraged to take immediate action as a class action lawsuit has been filed. The legal firm Wolf Haldenstein Adler Freeman & Herz LLP is leading this significant development, which could impact many shareholders.

As of March 3, 2026, the firm has announced that the lawsuit pertains to individuals and entities who acquired Zynex shares during the designated “Class Period,” which spans from February 25, 2021, to December 15, 2025. Investors only have until April 21, 2026, to apply for lead plaintiff status, making it crucial for affected shareholders to act quickly.

Core Allegations

The complaint against Zynex alleges several key violations of federal securities laws, primarily revolving around misleading statements and omissions made by the company's executives. Here are the core allegations:

1. Excess Product Shipments: The lawsuit claims that Zynex shipped more products, particularly medical electrodes, than were necessary, raising concern about the legitimacy of inventory claims.

2. Revenue Inflation: These excess shipments allegedly resulted in inflated revenue reports, misleading investors about the company’s financial health.

3. False Claims Scrutiny: Zynex's billing practices are under scrutiny from insurers, which could lead to serious repercussions for the company.

4. Litigation by Travelers: An action was filed against Zynex in California Superior Court alleging fraudulent overbilling practices, with demands for over $23 million in damages related to claims filed from 2018 to 2023.

5. Compliance Failures: The management of Zynex reportedly prioritized sales growth over regulatory compliance, neglecting necessary internal controls.

6. Improper Order Growth: Allegations suggest that the company’s reported order growth derived from improper overbilling practices.

7. Regulatory Risks: The lawsuit highlights the foreseeable risks Zynex faces, including potential removal from insurer networks and penalties from federal entities due to these practices.

8. Materially Misleading Statements: Overall, the lawsuit claims that the company's optimistic public statements were fundamentally grounded in misleading information regarding its operations and future prospects.

The Importance of Acting Quickly

For investors looking to get involved in the lawsuit, it is crucial to respond before the April deadline. Wolf Haldenstein, founded in 1888, emphasizes its unmatched experience in protecting investor rights, particularly in securities litigation. The firm is inviting all impacted investors who have information to assist in this case to reach out as soon as possible.

With over 125 years of expertise, Wolf Haldenstein is dedicated to ensuring that justice is served for investors misled by companies like Zynex. Investors can contact the firm via phone or email for more information:

- Phone: (800) 575-0735 or (212) 545-4774
- Email: [email protected]

In conclusion, if you are among those who sustained financial losses due to Zynex's practices, engaging with Wolf Haldenstein could be a vital step toward seeking restitution and holding the company accountable for its actions.